Cameron is top CAT
Executive Summary
AstraZeneca subsidiary Cambridge Antibody Technology appointed former AZ Head of Cardiovascular Therapy Area and Head of Medical Research Hamish Cameron as Chief Executive of CAT Limited, effective immediately, the company announced June 22. AstraZeneca acquired the biotech company as part of broader efforts to develop its biopharmaceuticals portfolio (1"The Pink Sheet" June 19, 2006, p. 9)...
You may also be interested in...
License To Fill: Pipeline Top AstraZeneca Priority Under Brennan
AstraZeneca's plans to bolster its product pipeline include further efforts to tap external technology sources, according to CEO David Brennan
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.